France: Aglaia Therapeutics, a biotechnology start-up developing therapies to overcome resistance to current targeted therapies in cancer patients, closed a €4m (US$4.7m) seed funding round. The round was led by Advent France Biotechnology (AFB) with participation from Crédit Mutuel Innovation and Pierre Fabre. Proceeds will be used to prepare the preclinical development programme required to identify the first…
©2022 All rights reserved LaingBuisson 
